Oroxylin A suppresses the glycolysis-dependent proliferation of breast cancer MDA-MB-231 cells by activating SRT3, and decreasing HIF-1α-targeted HK2 gene transcription (Wei et al., 2015). This evidence concerns the gene HIF1A and breast carcinoma.